Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arrowhead Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Announces JNJ-75220795 in Development for NASH
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.